WS #16512
Eli Lilly reported a robust Q3 with revenue of $24.4 billion, significantly beating estimates, driven by $10.7 billion in Mounjaro sales and $5.4 billion in Zepbound. The company raised its full-year revenue guidance to $91-92 billion, signaling sustained demand for its obesity treatments. This performance underscores the strength of the healthcare sector's growth story, providing a safe-haven bid in an otherwise volatile market dominated by tech uncertainty and geopolitical risks.
Eli Lilly Obesity Drug Dominance
Eli Lilly reported a robust Q3 with revenue of $24.4 billion, significantly beating estimates, driven by $10.7 billion in Mounjaro sales and $5.4 billion in Zepbound. The company raised its full-year revenue guidance to $91-92 billion, signaling sustained demand for its obesity treatments. This performance underscores the strength of the healthcare sector's growth story, providing a safe-haven bid in an otherwise volatile market dominated by tech uncertainty and geopolitical risks.